Parexel has joined forces with the Osaka International Cancer Institute to help “drive greater efficiencies” across trials in Japan.

Arcus inked an $816 million deal for a PD-1 drug developed by Chinese firms WuXi Biologics and Gloria Pharmaceuticals.

U.S. oncology specialist Cancer Genetics will pay $12 million to buy out Australian CRO vivoPharm as it looks to bolster its offerings.

SynteractHCR named Frank Santoro, M.D., who has more than 30 years of experience and most recently was Novella Clinical’s CMO, as its CMO.

DNA-encoded library technology expert HitGen just inked a multiyear, multitarget drug discovery deal with Aduro Biotech.

A BMJ paper has shown that progress is being made on clinical trial transparency, although there is still a way to go.

Takeda inked a multiyear, $170 million-per-program drug discovery partnership with Schrödinger.

GB Sciences will soon start human testing of three cannabis-derived formulations for Parkinson's, chronic pain and cardiovascular diseases.

A proof-of-concept study suggests that combines AI and the whole-genome sequencing of tumors could scale precision medicine for cancer.

Science Exchange will offer IndieBio-backed biotech startups access to its outsourced R&D platform.